FY2025 EPS Forecast for Xeris Biopharma Raised by Analyst

Key Points

• Analysts at Leerink Partners raised their FY2025 EPS estimate for Xeris Biopharma from ($0.05) to $0.01, while the consensus estimate is currently at ($0.41) per share.
• Xeris Biopharma recently reported quarterly earnings of ($0.01) EPS, surpassing analysts' expectations of ($0.03), with revenue of $67.71 million.
• Several research firms have upgraded their ratings and target prices for Xeris Biopharma, with five analysts rating the stock as a Buy and its average target price now at $6.58.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Research analysts at Leerink Partnrs lifted their FY2025 earnings per share estimates for Xeris Biopharma in a report issued on Tuesday, August 19th. Leerink Partnrs analyst R. Ruiz now expects that the company will earn $0.01 per share for the year, up from their prior forecast of ($0.05). The consensus estimate for Xeris Biopharma's current full-year earnings is ($0.41) per share. Leerink Partnrs also issued estimates for Xeris Biopharma's Q4 2025 earnings at $0.07 EPS, FY2026 earnings at $0.20 EPS, FY2027 earnings at $0.42 EPS and FY2028 earnings at $0.65 EPS.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.02. The firm had revenue of $67.71 million during the quarter, compared to analyst estimates of $64.58 million.

Several other equities research analysts also recently weighed in on XERS. HC Wainwright assumed coverage on Xeris Biopharma in a report on Tuesday, August 12th. They set a "buy" rating and a $10.00 price target for the company. Wall Street Zen upgraded shares of Xeris Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 9th. Leerink Partners boosted their price target on shares of Xeris Biopharma from $7.00 to $9.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 19th. Finally, Oppenheimer raised their price objective on shares of Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a research report on Friday, May 9th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, Xeris Biopharma currently has a consensus rating of "Moderate Buy" and a consensus target price of $7.08.

Xeris Biopharma Price Performance

Shares of XERS stock traded up $0.02 during trading hours on Friday, hitting $7.77. The stock had a trading volume of 1,953,434 shares, compared to its average volume of 2,553,253. The firm has a market capitalization of $1.25 billion, a PE ratio of -37.00 and a beta of 0.65. Xeris Biopharma has a twelve month low of $2.48 and a twelve month high of $7.96. The stock's 50 day moving average is $5.53 and its 200 day moving average is $4.86.

Insider Activity

In related news, Director John Johnson sold 107,500 shares of Xeris Biopharma stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $7.32, for a total transaction of $786,900.00. Following the completion of the transaction, the director directly owned 833,483 shares of the company's stock, valued at approximately $6,101,095.56. The trade was a 11.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Kevin Mcculloch bought 25,000 shares of the firm's stock in a transaction on Friday, June 13th. The shares were purchased at an average price of $4.38 per share, for a total transaction of $109,500.00. Following the completion of the transaction, the insider owned 1,708,585 shares of the company's stock, valued at $7,483,602.30. This represents a 1.48% increase in their position. The disclosure for this purchase can be found here. Insiders own 6.47% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in XERS. Wells Fargo & Company MN increased its position in shares of Xeris Biopharma by 38.7% in the fourth quarter. Wells Fargo & Company MN now owns 79,036 shares of the company's stock valued at $268,000 after buying an additional 22,050 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Xeris Biopharma by 1,496.3% in the fourth quarter. Russell Investments Group Ltd. now owns 17,974 shares of the company's stock valued at $61,000 after buying an additional 16,848 shares in the last quarter. Legal & General Group Plc increased its position in shares of Xeris Biopharma by 9.3% in the fourth quarter. Legal & General Group Plc now owns 230,467 shares of the company's stock valued at $781,000 after buying an additional 19,624 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Xeris Biopharma in the fourth quarter valued at $45,000. Finally, Barclays PLC increased its position in shares of Xeris Biopharma by 7.1% in the fourth quarter. Barclays PLC now owns 347,642 shares of the company's stock valued at $1,178,000 after buying an additional 23,170 shares in the last quarter. Hedge funds and other institutional investors own 42.75% of the company's stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.